摘要
目的探讨伊立替康（CPT-11）＋洛铂联合重组人血管内皮抑制素注射液治疗晚期复发小细胞肺癌（SCLC）的临床疗效。方法选取2012年7月至2014年7月间新疆维吾尔自治区人民医院收治的68例晚期复发SCLC患者,采用随机数字表法分为观察组（37例）和对照组（31例）。观察组患者接受CPT-11＋洛铂联合重组人血管内皮抑制素注射液治疗,对照组患者接受CPT-11＋洛铂治疗方案,观察并比较两组患者的疗效。结果观察组患者总有效率为59.5%,对照组为48.4%,组间差异无统计学意义（P〉0.05）。两组患者均有不良反应发生,且大都可以耐受,观察组患者白细胞下降和肝功能异常的发生率明显降低。观察组和对照组的中位无进展生存期（PFS）分别为8个月（95%CI为2.7-12.1）和5个月（95%CI为2.1-6.3）,组间差异无统计学意义（P=0.07）。观察组和对照组的总生存期（OS）分别为11.2个月（95%CI为0.9-52.6）和6.4个月（95%CI为7.8-16.9）,组间差异有统计学意义（P=0.04）。结论 CPT-11＋洛铂联合重组人血管内皮抑制素注射液治疗晚期复发小细胞肺癌的临床疗效较好,不良反应发生率较低,且可以延长患者的生存时间。
Objective To observe the clinical efficacy of irinotecan（ CPT-11）,lobaplatin and recombinant human endostatin injection for relapsed advanced-stage small cell lung cancer（ SCLC）. Methods From July 2012 to July 2014,68 patients with relapsed advanced-stage SCLC at Xinjiang Uygur Autonomous Region People＇s Hospital were selected and divided into an observation group（ n = 37） and a control group（ n = 31）. Patients in the observation group received CPT-11,lobaplatin and recombinant human endostatin injection,and those in the control group received CPT-11 combined with lobaplatin. Results The overall efficiency was 59. 5% for the observation group and 48. 4% for the control group（ P〈0. 05）. Adverse reactions occurred in both groups and most of them were tolerable. The incidence of leukopenia and liver disfunction in the observation group was significantly lower. The median progression-free survival was 8months for the observation group（ 95% CI： 2. 7-12. 1） and 5 months for the control group（ 95% CI： 2. 1-6. 3）（ P = 0. 07）. The overall survival in the observation group and the control group was 11. 2 months（ 95% CI： 0. 9-52. 6） and 6. 4 months（ 95% CI： 7. 8-16. 9） respectively（ P = 0. 04）. Conclusion The clinical efficiency of CPT-11,lobaplatin and recombinant human endostatin for relapsed advanced-stage SCLC is good with lower incidence of adverse reactions and prolonged survival rate.
出处
《中国肿瘤临床与康复》
2016年第11期1303-1306,共4页
Chinese Journal of Clinical Oncology and Rehabilitation
